How much does a box of Gilteritinib cost and the price differences in various regions?

Gilteritinib (Gilteritinib) is a FLT3 inhibitor, mainly used to treat patients with relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations. At present, the drug has been successfully launched in China, but because it has not yet been included in the medical insurance system, its clinical accessibility is subject to certain restrictions. If patients wish to purchase drugs through domestic hospital pharmacies, they may encounter difficulties due to channel and inventory issues. Therefore, many people will consider purchasing drugs overseas to obtain treatment.

In overseas markets, the original drug of gilitinib is supplied from Europe, Hong Kong, China and other regions. Especially the Hong Kong version of giritinib, its market price is very expensive. The price of one box is often as high as about 100,000 yuan, which brings a large financial burden to patients. Although original drugs have advantages in drug quality and brand trust, their prices have become an unbearable burden for most ordinary patients.

In contrast, generic versions of giritinib have been launched in some foreign markets, with the Laos version being the most common. The price of each box of generic drugs in Laos ranges from 1,000 yuan to 2,000 yuan, which is far lower than the pricing of original drugs. This price difference greatly alleviates the financial pressure on patients caused by long-term medication. It is worth noting that generic drugs are basically the same as the original drugs in terms of ingredients, and their efficacy and safety have been verified to a certain extent, so they are widely used by some patients in clinical practice.

Overall, the price of giritinib varies significantly in different regions. Although the original drug has stable quality, it is expensive, while the generic drug is more affordable and more acceptable to patients. Patients should comprehensively consider their financial ability, drug availability and doctor's advice when choosing, and never change drug channels on their own. During the medication process, hematological indicators and adverse reactions should be followed up regularly to ensure the effectiveness and safety of the treatment.

Reference materials:https://www.drugs.com/